Information Provided By: 
Fly News Breaks for October 7, 2015
ELGX
Oct 7, 2015 | 08:17 EDT
JPMorgan analyst Christopher Pasquale calls Endologix a stock to own into 2016. The company is "uniquely well positioned" to outperform over the next year into Nellix's anticipated FDA approval in the second half of 2016, Pasquale tells investors in a research note. He reiterates an Overweight rating on the stock with a $17 price target.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
